General Description

Vera Therapeutics

Youtube Subscribe

Ticker: VERA

Sector: Biotechnology

Firm is focused on developing treatments for Lupus Nephritis. Firm is expected to participate in the 44th Annual Goldman Sachs Global Healthcare Conference. CFO Sean Grant made headlines with his purchase of 5,000 shares of the companies stock on.

Extended Summary

Vera Therapeutics

Jump Financial LLC increased its holdings in Vera Therapeutics by an astonishing 199.4% during the first quarter. CFO Sean Grant made headlines with his purchase of 5,000 shares of the companys stock on Friday, June 23rd. Commodore Capital Lp purchased 448,217 shares at an average price of $15.17 per share. Vera Therapeutics to Participate in the 44th Annual Goldman Sachs Global Healthcare Conference. Analyst Consensus: Buy Stock Forecasts: Buy stock Forecasts News All Videos Press Press Press Releases. Vera Therapeutics (NASDAQ: VERA) operates as a clinical-stage biotechnology company. Firm is focused on developing treatments for Lupus Nephritis. Vera Therapeutics, Inc. (VERA) stock price today, quote & news | Seeking Alpha. Join the Summer Sale! Skip to content. Find & Compare Top Stocks. Raymond James & Associates purchased 25,285 shares of Vera Therapeutics stock during the 1st quarter of this year. At the end of the reporting period, Raymond James and Associates boasted ownership of approximately 0.06% of the company. Vera Therapeutics Inc - Ordinary Shares - Class A 853 $18.41 $0.41 (2.28%) Today Watchers 853 52-Wk Low $5.20 52- Wk High $23.39 Sentiment 75.00% Message Vol. 22.22% Market Cap $814.85M Volume (M) 242,193.

Related Results

March 10, 2024 18:10 (London Time)